Prothena Co. PLC (NASDAQ:PRTA) has earned an average recommendation of “Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $74.75.
Several equities research analysts have issued reports on PRTA shares. Wedbush downgraded Prothena from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $75.00 to $55.00 in a report on Monday, November 20th. Oppenheimer set a $70.00 price objective on Prothena and gave the stock a “buy” rating in a report on Monday, December 4th. ValuEngine downgraded Prothena from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Zacks Investment Research downgraded Prothena from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $65.00 price objective on shares of Prothena in a report on Wednesday, December 20th.
Several institutional investors and hedge funds have recently modified their holdings of PRTA. Woodford Investment Management Ltd grew its position in shares of Prothena by 1.6% in the 4th quarter. Woodford Investment Management Ltd now owns 11,528,614 shares of the biotechnology company’s stock worth $325,223,000 after acquiring an additional 179,000 shares in the last quarter. Sphera Funds Management LTD. boosted its position in Prothena by 241.7% during the 4th quarter. Sphera Funds Management LTD. now owns 205,000 shares of the biotechnology company’s stock valued at $7,685,000 after purchasing an additional 145,000 shares during the period. Alliancebernstein L.P. boosted its position in Prothena by 11.2% during the 4th quarter. Alliancebernstein L.P. now owns 1,005,998 shares of the biotechnology company’s stock valued at $37,715,000 after purchasing an additional 101,273 shares during the period. Deutsche Bank AG boosted its position in Prothena by 37.8% during the 4th quarter. Deutsche Bank AG now owns 231,468 shares of the biotechnology company’s stock valued at $8,674,000 after purchasing an additional 63,537 shares during the period. Finally, First Manhattan Co. boosted its position in Prothena by 114.4% during the 4th quarter. First Manhattan Co. now owns 107,200 shares of the biotechnology company’s stock valued at $4,018,000 after purchasing an additional 57,200 shares during the period.
Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Wednesday, February 14th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.48) by $0.24. Prothena had a negative return on equity of 33.37% and a negative net margin of 556.84%. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.27 million. During the same period in the previous year, the business earned ($1.41) EPS. Prothena’s revenue for the quarter was up 33.9% compared to the same quarter last year. equities analysts anticipate that Prothena will post -5.87 earnings per share for the current fiscal year.
Prothena Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.